HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version

Size: px
Start display at page:

Download "HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM. Version"

Transcription

1 1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) NON-IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: ADULT HIV 900 (AIDS.gov 12/31/2015) HIV Lifelong HIV (human immunodeficiency virus) is a retrovirus with two serologically and geographically distinct species: HIV- 1 and HIV-2. It is spread via person-to-person transmission through: sexual contact, the use of HIV-contaminated needles and syringes, vertical transmission from mother to infant, or the transfusion of infected blood or its components. If left untreated, HIV can progress to the disease AIDS (acquired immunodeficiency syndrome). Unlike some other viruses, the human body cannot get rid of HIV completely. HIV attacks the body s immune system, specifically the CD4 cells (T cells). If left untreated, HIV reduces the number of CD4 cells in the body, making the person more likely to get infections or infection-related cancers. These opportunistic infections or cancers take advantage of the weakened immune system and signal that the person has AIDS (the advanced stage of HIV infection). The incubation period is variable, although the time from infection to the development of detectable antibodies is generally less than one month. The time from HIV infection to diagnosis of AIDS, in the absence of antiretroviral treatment, has an observed range less than 1 year to 15 years or longer, with an average of about ten years from infection to an AIDS diagnosis. Positive HIV 1, Positive HIV 2, or Positive (Undifferentiated) HIV result from a differentiating immunoassay, Western Blot, IFA, or culture OR Positive/Detected Qualitative HIV NAT (DNA or RNA) OR Quantitative HIV NAT (detectable viral load assay) Probable Complete CRF received with MD confirmed diagnosis, no confirmatory lab Positive Ag/Ab screen, Positive EIA, Positive p24ag, undetectable viral load, or CD4 Revoked Inappropriately created case, not an MA case, cancer, CD4 only PEDIATRIC HIV- 900P <13 years old Probable Revoked *If case is less than 13 years old, alert the HIV liaison Two Positive HIV virologic test (HIV 1 NAT, HIV 1 p24, culture) results from 2 different specimens obtained on different dates Single Positive HIV virologic test (HIV 1 NAT, HIV 1 p24, culture) Positive Ab in <18 month olds) Inappropriately created case, not an MA case, cancer

2 2 ADULT AIDS (AIDS.gov 12/31/2015) AIDS stands for acquired immunodeficiency syndrome. AIDS is the advanced stage of HIV infection, and not everyone who has HIV advances to this stage. AIDS is the stage of infection that occurs when your immune system is compromised and you become vulnerable to opportunistic infections. When your CD4 cells falls below 200 cells per cubic millimeter of blood (200 cells/mm3), you are considered to have progressed to AIDS (rmal CD4 counts are between 500 and 1,600 cells/mm3). You can also be diagnosed with AIDS if you develop one or more opportunistic infections, regardless of your CD4 count. evidence of HIV and complete CRF received AND CD4 absolute count <200 (or in absence of CD4 absolute count, CD4 percent below 14%) AND/OR an opportunistic infection diagnosis Probable Complete CRF received with MD confirmed diagnosis, no confirmatory lab CD4 absolute count <200 (or in absence of CD4 absolute count, CD4 percent below 14%) Revoked Inappropriately created case, not an MA case, cancer, CD4 only PEDIATRIC AIDS 950P <13 years old Probable Revoked *If case is less than 13 years old, alert the HIV liaison See case classification for adult AIDS See case classification for adult AIDS See case classification for adult AIDS Inappropriately created case, not an MA case, cancer

3 Report Type Test Type Source Result Laboratory report HIV-1/2 Ab/Ag screen (4 th gen) Blood, serum, saliva Positive, Reactive 3 New event? Data Entry Select: HIV 1+2 Ab HIV1 p24 Ag: ACnc : Pt : Ser : Ord : EIA HIV-1/2 Ag/Ab screening HIV 1 Ab+Ag [Presence] in Serum HIV-1/2 Ag/Ab screening Laboratory report EIA, ELISA Blood, serum, saliva Positive Select: HIV 1+2 Ab [Presence]: ACnc : Pt : XXX : Ord HIV-1/2 IA (EIA or Other) HIV 1+O+2 Ab [Presence] : ACnc : Ser/Plas : Ord HIV-1/2 IA (EIA or Other) HIV 1 Ab [Units/volume] : ACnc : Pt : Ser : Qn : EIA HIV-1 IA (EIA or Other) HIV 1 Ab : ACnc : Pt : Body fld : QI : Ord HIV-1 IA (EIA or Other) HIV 2 Ab [Presence] : ACnc: Pt : Ser : QI : Ord : EIA HIV-2 IA (EIA or Other) Laboratory report HIV-1 p24 Antigen Blood, serum, saliva Positive Select: HIV 1 p24 Ag [Presence] : ACnc : Pt : CSF : Ord HIV-1 p24 Antigen HIV 1 P24 Ag : ACnc : Pt : Ser : QI : Ord : EIA HIV-1 p24 Antigen HIV 1 P24 Ag [Mass/volume] : MCnc : Ser : Qn : EIA HIV-1 p24 Antigen HIV 1 P24 Ag Ser Ql HIV-1 p24 Antigen HIV 1 P24 Ag : ACnc : Pt : CSF : Qn HIV-1 p24 Antigen

4 Report Type Test Type Source Result Laboratory report Laboratory report Laboratory report HIV-1/2 Type- Differentiating Immunoassay Blood, serum, saliva HIV 1 RNA [Units/volume] (viral load) (Quant bdna) in Plasma by Probe and signal amplification method 4 Positive (undifferentiated HIV), Human Immunodeficiency Virus, Human Immunodeficiency Virus Type 1, Human Immunodeficiency Virus Type 2, Human Immunodeficiency Virus 2 positive with HIV-1 cross reactivity Indeterminate, Human Immunodeficiency Virus 1 Indeterminate, Human Immunodeficiency Virus 2 Indeterminate New event? Data Entry Any of the above, negative, inconclusive, not detected Select: HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay Multispot type differentiating HIV 1 and 2 Ab in Serum/Plasma/Blood by Rapid immunoassay Geenius Assay type differentiating HIV 1 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay Geenius Analyte HIV-1 HIV 2 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay Geenius Analyte HIV-2 Positive (undifferentiated HIV), Western Blot, Blood, serum, Human Immunodeficiency Virus, IFA saliva Human Immunodeficiency Virus Type 1, Human Immunodeficiency Virus Type 2 Select: HIV 1 & 2 Ab band pattern [interpretation] : Imp : Pt : Ser : m : IB Differentiating Western blot HIV 1 Ab [Presence] : ACnc : Pt : Body fld : Ord : IB HIV-1 Western Blot HIV 2 IgG Ab [Presence] : ACnc: Pt : Ser : Ord : IB HIV-2 Western Blot HIV 2 Ab [Presence] : ACnc : Pt: Ser : Ord : IB HIV-2 Western Blot HIV 1 Ab: ACnc: Pt: Ser: Ord: IF HIV-1 Immunofluorescence HIV-1 RNA Quantitative NAAT viral load Blood, serum, saliva A numeric value by itself, or a numeric value with a = or a > symbol Numeric value with a less than < symbol indicating an undetectable viral load Any of the above Select: HIV 1 RNA [#/volume] (viral load) : NCnc : Pt : XXX : Probe.amp.tar HIV 1 RNA [Log #/volume] (viral load) : LnCnc : Pt : XXX : Qn : Probe.amp.tar HIV-1 viral load (Quantitative) HIV-1 viral load log copies(quantitative) HIV-1 viral load copies(quantitative)

5 5 New Data Report Type Test Type Source Result event? Entry Detected, Trace, Positive HIV-1 or HIV-2 Laboratory report Qualitative NAT Blood, serum, saliva Undetectable, t detected, Negative, (DNA or RNA) Indeterminate existing event HIV-1 viral load (detected or Select: HIV 1 RNA [#/volume] (viral load) : NCnc : Pt : XXX : Probe.amp.tar trace)(qualitative) HIV 1 RNA [Log #/volume] (viral load) : LnCnc : Pt : XXX : Qn : HIV-1 viral load (detected or Probe.amp.tar trace)(qualitative) HIV 1 RNA [Units/volume] (viral load) (Quant bdna) in Plasma by HIV-1 viral load (detected or Probe and signal amplification method trace)(qualitative) HIV 1 RNA [Presence] : ACnc : Pt : XXX : Ord : Probe.amp.tar HIV-1 RNA/DNA NAT (Qualitative) Laboratory report HIV 1 DNA [Presence] : ACnc : Pt : Ser/Plas : Probe.amp.tar HIV-1 RNA/DNA NAT (Qualitative) HIV 2 DNA Bld Ql PCR HIV-2 RNA/DNA NAT (Qualitative) HIV 2 DNA [Presence] : ACnc : Pt : XXX : Probe.amp.tar HIV-2 RNA/DNA NAT (Qualitative) CD4 absolute count CD4 percent Blood, serum, saliva Numeric result only Select: Deprecated CD4 cells [#/volume]: NCnc : Pt: XXX : Qn CD4 absolute count Deprecated CD4 cells [/100 Cells] : NFr : Pt: XXX : Qn CD4 percent existing event Laboratory report Culture Blood, serum, saliva Human Immunodeficiency Virus, Human Immunodeficiency Virus Type 1, Human Immunodeficiency Virus Type 2 Select: Virus identified : PrId : Pt : xxx : m : Virus culture Virus culture Microorganism identified : PrId : Pt : xxx : m : Culture Microorganism culture existing event

6 6 ADDITIONAL NOTES: Incident case: A newly reported individual living in Massachusetts, reported within the calendar year, with a diagnosis date within that calendar year Prevalent case: A newly reported individual living in Massachusetts, reported within the calendar year, with a diagnosis date outside of that calendar year Opportunistic infections: Bacterial infection, multiple or recurrent (including Salmonella septicemia) Candidiasis of the lung Candidiasis, Esophogeal Cervical cancer Coccidioidomycosis Cryptococcosis Cryptosporidiosis Cytomegalovirus disease Cytomegalovirus retinitis HIV encephalopathy Herpes simplex Histoplasmosis Isosporiasis Kaposi s sarcoma Lymphoid interstitial pneumonitis Lymphoma, Burkitt s Lymphoma, immunoblastic Lymphoma, primary in brain Mycobacterium avium complex M. Tuberculosis, pulmonary M. Tuberculosis, disseminated Mycobacterium, other species Pneumocystis pneumonia (PCP) Pneumonia (any organism), recurrent Progressive leukoencephalopathy Salmonella septicemia Toxoplasmosis of brain HIV Wasting Syndrome

Title: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years

Title: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years 06-ID-02 Committee: Infectious Disease Title: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years Statement of problem: Advances in HIV

More information

HEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM

HEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM HEPATITIS B NON-IMMEDIATE NOTIFICATION EPIDEMIOLOGY PROGRAM Event Name: Event Time Period: ACUTE Clinical Presentation (CDC 2012): CDC Event (2012): HEPB Lifelong immunity An acute illness with a discrete

More information

10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission

10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission Chapter 55 Care of the Patient with HIV/AIDS All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. History of HIV Remains somewhat obscure The earlier

More information

Measure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy

Measure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy Measure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy 2012 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION:

More information

QUARTERLY HIV/AIDS SURVEILLANCE REPORT

QUARTERLY HIV/AIDS SURVEILLANCE REPORT QUARTERLY HIV/AIDS SURVEILLANCE REPORT San Francisco Department of Public Health HIV/AIDS Cases Reported Through September 2010 Contents Page Surveillance Summary..... 1 Table 1: Adult/Adolescent HIV/AIDS

More information

http://www.savinglivesuk.com/ HIV Awareness Study Morning 24 th November 2017 Agenda HIV Basics & Stages of HIV HIV Testing, Health Advising & Sexual Health Saving Lives Antiretroviral Medication Antenatal/Postnatal

More information

QUARTERLY AIDS SURVEILLANCE REPORT

QUARTERLY AIDS SURVEILLANCE REPORT QUARTERLY AIDS SURVEILLANCE REPORT San Francisco Department of Public Health AIDS Cases Reported Through June 2010 0 Contents Page Surveillance Summary..... 1 Table 1: Adult/Adolescent AIDS Cases by Transmission

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.

More information

medical monitoring: clinical monitoring and laboratory tests

medical monitoring: clinical monitoring and laboratory tests medical monitoring: clinical monitoring and laboratory tests Purpose of monitoring Check on the physical, psychological and emotional condition of the patient Detect other treatable conditions Identify

More information

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016 New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new

More information

Immunodeficiencies HIV/AIDS

Immunodeficiencies HIV/AIDS Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement

More information

Presented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST

Presented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST Presented by: Melissa Egan, Regional Health Education Coordinator, CATIE Date: Tuesday October 8th, 2013, 1 2pm EST Agenda 1. HIV and the immune system 2. The progression of untreated HIV 3. Monitoring

More information

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC) HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC

More information

R EVISION OF CDC/WHO CASE DEFINITION FOR ACQUIRED IMMUNODEFICIENCY SYNDROME-(AIDS) :

R EVISION OF CDC/WHO CASE DEFINITION FOR ACQUIRED IMMUNODEFICIENCY SYNDROME-(AIDS) : ity of the introduction of infection is low, but if it were introduced, current levels of domestic water contact would ensure transmission. Trinidad and Tobago. The potential intermediate host present

More information

OI prophylaxis When to start, when to stop. Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco

OI prophylaxis When to start, when to stop. Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco OI prophylaxis When to start, when to stop Eva Raphael, MD MPH Family and community medicine, pgy-2 University of California, San Francisco Learning Objectives o Recognize when to start OI prophylaxis

More information

NEW PATIENT REGISTRATION

NEW PATIENT REGISTRATION NEW PATIENT REGISTRATION Hospital No. Date of Visit : / / Surname : First Name : Date of birth : / / Country of Birth : Sex : Male Female Transman Transwoman Other (please specify): Is this patient from

More information

Doctor, I Have Strep Throat. Nancy W Weber D.O. FACOEP FACEP MBA Sparrow/MSU Emergency Medicine Residency October 22, 2018

Doctor, I Have Strep Throat. Nancy W Weber D.O. FACOEP FACEP MBA Sparrow/MSU Emergency Medicine Residency October 22, 2018 Doctor, I Have Strep Throat Nancy W Weber D.O. FACOEP FACEP MBA Sparrow/MSU Emergency Medicine Residency October 22, 2018 Disclosures None The Patient: 41YOF CC: Sore throat x 3 days HPI: Sore throat increasing

More information

Defining AIDS. Defining AIDS HIV 3 DECADES LATER. Adversity reveals genius, prosperity conceals it. Horace

Defining AIDS. Defining AIDS HIV 3 DECADES LATER. Adversity reveals genius, prosperity conceals it. Horace w w w. I C A 2 0 1 4. o r g Adversity reveals genius, prosperity conceals it. Horace HIV 3 DECADES LATER Effects on the Life Business in Kenya - by Luke Wanjohi After more than 30 years of HIV pandemic

More information

Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013

Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions

More information

San Francisco AIDS Cases Reported Through December 31, 1998

San Francisco AIDS Cases Reported Through December 31, 1998 San Francisco AIDS Cases Reported Through December 31, 1998 San Francisco Department of Public Health HIV Seroepidemiology and Surveillance Section AIDS Surveillance Unit Contents Page Commentary: Trends

More information

The Italian AIDS Epidemic Supports The Chemical AIDS Theory. Daniele Mandrioli

The Italian AIDS Epidemic Supports The Chemical AIDS Theory. Daniele Mandrioli The Italian AIDS Epidemic Supports The Chemical AIDS Theory Daniele Mandrioli EPIDEMIOLOGY France Population: 65.073.482 AIDS Incidence: 16/million Germany Population: 82.438.000 AIDS Incidence: 4/million

More information

Complicated viral infections

Complicated viral infections Complicated viral infections Clinical case discussion Diagnostic dilemmas NSW State Reference Laboratory for HIV St Vincent s Hospital Sydney Diagnostic dilemmas Indeterminate or discordant serology (western

More information

Chapter 22. Autoimmune and Immunodeficiency Diseases

Chapter 22. Autoimmune and Immunodeficiency Diseases Chapter 22 Autoimmune and Immunodeficiency Diseases Autoimmune Diseases Failures of self-tolerance Immune system fails to distinguish selfantigens from foreign antigens This results in the immune system

More information

STRATEGIES INFECTIONS

STRATEGIES INFECTIONS STRATEGIES FOR MANAGING OPPORTUNISTIC INFECTIONS ways to help prevent and treat opportunistic infections A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008

More information

New HIV Tests and Algorithm: A change we can believe in

New HIV Tests and Algorithm: A change we can believe in New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be

More information

INTEGRATING HIV INTO PRIMARY CARE

INTEGRATING HIV INTO PRIMARY CARE INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.

More information

HIV Testing Technology and the Latest Algorithm

HIV Testing Technology and the Latest Algorithm HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with

More information

Human Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS

Human Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s

More information

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd

More information

Trends in molecular diagnostics

Trends in molecular diagnostics Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling

More information

Cancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health

Cancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health Cancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health Main collaborators Lesley Park Janet Tate Amy Justice Michael

More information

San Francisco Department of Public Health. Level I Data Requirements (Applicable to All Agencies)

San Francisco Department of Public Health. Level I Data Requirements (Applicable to All Agencies) San Francisco Department of Public Health HIV Health Services (HHS) ARIES Registration Form Level I Data Requirements (Applicable to All Agencies) Client Name: Last First Middle Name Mother s Maiden Name

More information

OUTCOME CODES FOR MACS STATUS FORM

OUTCOME CODES FOR MACS STATUS FORM OUTCOME CODES FOR MACS STATUS FORM CODE CDC-DEFINED AIDS DIAGNOSES (Section C) 01 Kaposi's sarcoma 02 Pneumocystis carinii pneumonia 03 Toxoplasmosis (at a site other than or in addition to liver, spleen,

More information

Welcome to Carolinas CARE Partnership. HIV A to Z: 6/30/2015. Objectives. The Basics and Beyond. Introductions Pre-Test Expectations

Welcome to Carolinas CARE Partnership. HIV A to Z: 6/30/2015. Objectives. The Basics and Beyond. Introductions Pre-Test Expectations Welcome to Carolinas CARE Partnership HIV A to Z: The Basics and Beyond Introductions Pre-Test Expectations Objectives Distinguish and define HIV and AIDS Brief history of the origin of HIV and AIDS Explain

More information

Other Diagnostic Tests

Other Diagnostic Tests Other Diagnostic Tests APTIMA HIV-1 RNA Qualitative Assay (approved in Oct 2006) Confirmation test (like Western Blot) Detects RNA of the HIV-1 virus (Nucleic Acid Amplification Test/ NAAT) First test

More information

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead: CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled

More information

958 HIV: The Initial Physician-Patient Encounter Mayo Clin Proc, September 2002, Vol 77 Table 1. Indications for HIV Screening* High-risk behaviors Mu

958 HIV: The Initial Physician-Patient Encounter Mayo Clin Proc, September 2002, Vol 77 Table 1. Indications for HIV Screening* High-risk behaviors Mu Mayo Clin Proc, September 2002, Vol 77 HIV: The Initial Physician-Patient Encounter 957 Concise Review for Clinicians Human Immunodeficiency Virus: The Initial Physician-Patient Encounter MARY J. KASTEN,

More information

HIV Diagnostic Testing

HIV Diagnostic Testing In The name of God HIV Diagnostic Testing By : Dr. Shahzamani PhD of Medical virology Purpose of HIV Testing To identify asymptomatic individuals To diagnose HIV infection in those who practice high risk

More information

Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems

Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems Highlight Disease: Malaria World s dominant protozoal disease. Four species of Plasmodium: P. falciparum (malignant), P. vivax (begnin),

More information

Sexually Transmi/ed Diseases

Sexually Transmi/ed Diseases Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human

More information

Immunodeficiency. (2 of 2)

Immunodeficiency. (2 of 2) Immunodeficiency (2 of 2) Acquired (secondary) immunodeficiencies More common Many causes such as therapy, cancer, sarcoidosis, malnutrition, infection & renal disease The most common of which is therapy-related

More information

Clinical Manifestations of HIV

Clinical Manifestations of HIV HIV Symptoms Diane Havlir, MD Professor of Medicine and Chief, HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 2, 2013 1 Clinical Manifestations of HIV! Result from

More information

LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES HIV EPIDEMIOLOGY PROGRAM

LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES HIV EPIDEMIOLOGY PROGRAM DEPARTMENT OF HEALTH SERVICES HIV EPIDEMIOLOGY PROGRAM ADVANCED HIV DISEASE (AIDS) QUARTERLY SURVEILLANCE SUMMARY Cases Reported as of March 31, 2001 Issued April 15, 2001 600 S. Commonwealth Ave., Suite

More information

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation

List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation Alere (honoraria) List the steps in the fourth generation HIV screening algorithm Describe the relationship between rapid HIV antibody tests and the fourth generation testing algorithm Interpret challenging

More information

A Summary of Clinical Evidence

A Summary of Clinical Evidence A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table

More information

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES

Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Diagnosing HIV Infection AMNERIS E. LUQUE, M.D. PROFESSOR OF MEDICINE/INFECTIOUS DISEASES MEDICAL DIRECTOR, PARKLAND HIV SERVICES Disclosures None Objectives 1. Outline the CDC recommendations for HIV

More information

Adventures in Discordance- HIV Testing

Adventures in Discordance- HIV Testing Anne Gaynor, PhD On behalf of Monica M. Parker, PhD Director, Bloodborne Viruses Laboratory Wadsworth Center, NYSDOH Adventures in Discordance- HIV Testing HIV Laboratory Testing Algorithm HIV-1/2 antigen/antibody

More information

Diagnostic Tests for HIV

Diagnostic Tests for HIV Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,

More information

SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM

SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: Clinical Description (CDC 2014) Syphilis 180 days Syphilis is a complex sexually transmitted disease that

More information

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ www.micropathology.com info@micropathology.com Micropathology Ltd Tel 24hrs: +44 (0) 24-76 323222 Fax / Ans: +44 (0) 24-76 - 323333 University of Warwick Science Park, Venture Centre, Sir William Lyons

More information

HIV/AIDS 101. HIV Case Manager Portal. Current as of March 2014.

HIV/AIDS 101. HIV Case Manager Portal. Current as of March 2014. *Photographs used for this presentation do not depict actual patients or health care professionals. Current as of March 2014. HIV/AIDS 101 HIV Case Manager Portal HIV/AIDS in the United States Almost every

More information

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention New Generation of Nucleic Acid Testing Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention Percentage (%) Persons Living with Diagnosed or Undiagnosed HIV Infection

More information

HIV Transmission HASPI Medical Biology Lab 20

HIV Transmission HASPI Medical Biology Lab 20 HIV Transmission HASPI Medical Biology Lab 20 Background History of HIV/AIDS Acquired Immune Deficiency Syndrome (AIDS) was first seen in 1981 when large numbers of people with two rare diseases surfaced:

More information

AIDS. urvival. Hepatitis C. Race/Ethnicity. Women. revalence. Morbidity TRENDS. Transgender MEN HAART. Men who have sex with men. Injection Drug Use

AIDS. urvival. Hepatitis C. Race/Ethnicity. Women. revalence. Morbidity TRENDS. Transgender MEN HAART. Men who have sex with men. Injection Drug Use Injection Drug Use Homeless IV Transgender Hepatitis C Mortality Sexually transmitted diseases revalence San Francisco Department of Public Health Heterosexuals HIV/AIDS Epidemiology Annual Report 2002

More information

HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis

HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis Product Manual HIV-1 Genemer Detection Kit Ready to Use Amplification Kit for HIV-1 Specific DNA Fragment Analysis For research use only. Not for use in diagnostic procedures for clinical purposes Catalog

More information

HIV A 2017 Update Bill Rooney MD SCOR Global Life

HIV A 2017 Update Bill Rooney MD SCOR Global Life NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing

More information

Updates in HIV Medicine. Dr. Jacky Chan Associate Consultant Princess Margaret Hospital

Updates in HIV Medicine. Dr. Jacky Chan Associate Consultant Princess Margaret Hospital Updates in HIV Medicine Dr. Jacky Chan Associate Consultant Princess Margaret Hospital What is HIV? HIV - Human immunodeficiency virus Retrovirus Human Immunodeficiency virus type-1 (HIV-1) Global AIDS

More information

The importance of cohort collaborations for guiding clinical management of individuals with HIV infection

The importance of cohort collaborations for guiding clinical management of individuals with HIV infection The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College

More information

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests

Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

2018 HIV and HCV Diagnostic Testing Survey

2018 HIV and HCV Diagnostic Testing Survey 2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will

More information

Case Definition and Lab Tests

Case Definition and Lab Tests Chapter 7 Case Definition and Lab Tests 7-1 Test types Laboratory tests are available to diagnose HIV infection, as well as to monitor health status after HIV diagnosis. Diagnostic tests look for an immune

More information

Technical Bulletin No. 104b

Technical Bulletin No. 104b CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 104b June 22, 2016 Update to Guidelines for Diagnosing HIV Infection CPAL s Testing Algorithm for Diagnostic HIV Testing HIV Geenius

More information

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003 Chapter 13 Viruses, Viroids, and Prions Biology 1009 Microbiology Johnson-Summer 2003 Viruses Virology-study of viruses Characteristics: acellular obligate intracellular parasites no ribosomes or means

More information

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital HIV Lecture Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital End-2001 global estimates for children and adults People living with HIV/AIDS New HIV infections in

More information

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes

More information

CHIPS APPENDICES: VERSION 2.4

CHIPS APPENDICES: VERSION 2.4 CHIPS APPENDICES: VERSION 2.4 Page number Appendix 1 CDC classification of stages N, A and B 1 Appendix 2 CDC classification of stage C (AIDS) 2 Appendix 3 Definition of body fat changes 3 Appendix 4 Reason

More information

Amsterdam Cohort Studies among homosexual men and drug users

Amsterdam Cohort Studies among homosexual men and drug users Public dataset description. Amsterdam Cohort Studies among homosexual men and drug users Introduction The Amsterdam cohort study (ACS) on human immunodeficiency virus (HIV) infection and AIDS among homosexual

More information

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is

More information

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22

HIV Serology Quality Assessment Program Summary for Panel HIVS Oct22 National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary

More information

The Human Immunodeficiency Virus and the Colon and Rectal Surgeon

The Human Immunodeficiency Virus and the Colon and Rectal Surgeon The Human Immunodeficiency Virus and the Colon and Rectal Surgeon David A. Margolin, M.D. 1 ABSTRACT A knowledge of the human immunodeficiency virus (HIV) is important in colon and rectal surgery. This

More information

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis

RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O

More information

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018 Shipping and Submission Instructions Thank you for participating as a submitting

More information

Routine HIV Testing Community of Practice Session #2

Routine HIV Testing Community of Practice Session #2 Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing

More information

HIV CME. Sarah Barbour, MD Orlando Health Infectious Disease Fellowship Program

HIV CME. Sarah Barbour, MD Orlando Health Infectious Disease Fellowship Program HIV CME Sarah Barbour, MD Orlando Health Infectious Disease Fellowship Program Disclosures No conflicts of interest Objectives Briefly review basic science Discuss epidemiology of HIV Discuss modes of

More information

Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease

Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease Faculty representative: Eva Piessens, MD, MPH Resident representative: Karen Ganz, MD Revision date: February 1, 2006

More information

Improving quality of services and retention in HIV care and treatment: Severely immunosuppressed package of care (SIPOC)

Improving quality of services and retention in HIV care and treatment: Severely immunosuppressed package of care (SIPOC) Improving quality of services and retention in HIV care and treatment: Severely immunosuppressed package of care (SIPOC) Dr. Maureen Syowai Kathuku-Kaati December 2015 Objectives 1. To understand the mechanism

More information

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What

More information

Human Immunodeficiency Virus Serology

Human Immunodeficiency Virus Serology Participant No: _ Human Immunodeficiency Virus Serology Survey No: RT :20 Please print the document labelled Clinical Notes & Test Instructions and enter your results via myqap. Kit Information Please

More information

8/10/2017. HIV UPDATE 2017 David M Stein DO, FACOI

8/10/2017. HIV UPDATE 2017 David M Stein DO, FACOI HIV UPDATE 2017 David M Stein DO, FACOI 1 Current US HIV data 1.1 million HIV positive 1 out of 7 positive are unaware of their status Highest risk in Gay and Bisexual men, young African American men 2

More information

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad

Immunologic Methods in Diagnosis of HIV Infection. Tehran Medical Sciences Branch, Islamic Azad Immunologic Methods in Diagnosis of HIV Infection M Parsania, Ph.D. Tehran Medical Sciences Branch, Islamic Azad University Retroviridae Retroviruses (family Retroviridae) id ) are enveloped, single stranded

More information

Human Immunodeficiency Virus-1 (HIV-1) Genemer. Primer Pair for amplification of HIV-1 Specific DNA Fragment

Human Immunodeficiency Virus-1 (HIV-1) Genemer. Primer Pair for amplification of HIV-1 Specific DNA Fragment Product Manual Human Immunodeficiency Virus-1 (HIV-1) Genemer Primer Pair for amplification of HIV-1 Specific DNA Fragment Catalog No.: 60-2002-10 Store at 20 o C For research use only. Not for use in

More information

Can we treat our way out of the HIV epidemic?

Can we treat our way out of the HIV epidemic? Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question

More information

Viruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae

Viruses. Poxviridae. DNA viruses: 6 families. Herpesviridae Adenoviridae. Hepadnaviridae Papovaviridae Parvoviridae Viruses DNA viruses: 6 families Poxviridae Herpesviridae Adenoviridae Hepadnaviridae Papovaviridae Parvoviridae Human herpesviruses Three subfamilies (genome structure, tissue tropism, cytopathologic effect,

More information

Medical monitoring: Clinical monitoring and laboratory tests

Medical monitoring: Clinical monitoring and laboratory tests medical monitoring: clincial monitoring and laboratory tests: 1 medical monitoring: clinical monitoring and laboratory tests Medical monitoring: Clinical monitoring and laboratory tests Aims This section

More information

Overview of HIV Testing Practices and Technology

Overview of HIV Testing Practices and Technology Overview of HIV Testing Practices and Technology 2019 HIV Diagnostics Conference March 25 th, 2019 Michele Owen, Ph.D National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease

More information

HIV- INFECTION WHO case definition for HIV infection 2007 Adults and children 18 months or older HIV infection is diagnosed based on:

HIV- INFECTION WHO case definition for HIV infection 2007 Adults and children 18 months or older HIV infection is diagnosed based on: HIV- INFECTION Human immunodeficiency virus (HIV) is a blood-borne, sexually transmissible virus (see the image below.) The virus is typically transmitted via sexual intercourse, shared intravenous drug

More information

LSOCA General Knowledge Assessment

LSOCA General Knowledge Assessment General Knowledge Assessment A. Enrollment 1. Which of the following is/are the inclusion criteria(s) for (check all that apply): ( 1) Participant must be at least 13 years of age ( 1) Participant must

More information

HIV/AIDS Primer for Nurse Practitioners Nursing is Attending to Meaning. Bill Wade R.N June 21,2005.

HIV/AIDS Primer for Nurse Practitioners Nursing is Attending to Meaning. Bill Wade R.N June 21,2005. HIV/AIDS Primer for Nurse Practitioners Nursing is Attending to Meaning Bill Wade R.N June 21,2005. 1 Goals of this presentation Offer minimum content levels to enhance your learning needs around HIV/AIDS

More information

Webinar. Cellular Medicine & HIV/AIDS. Fabrice Leu N.D

Webinar. Cellular Medicine & HIV/AIDS. Fabrice Leu N.D Webinar Cellular Medicine & HIV/AIDS Fabrice Leu N.D Summary What is HIV? What is AIDS? What causes HIV/AIDS? What is the orthodox medical approach? How to stop AIDS with Cellular Medicine Dr. Rath s book

More information

2. Clinical Manifestations (Pediatric HIV Infection)

2. Clinical Manifestations (Pediatric HIV Infection) Page 1 of 6 HOUSTON ROMANIA SOUTHERN AFRICA MEXICO HOME CONTACT Friday, July 25, 2003 Pediatric HIV Infection by Mark W. Kline, M.D. 1. Introduction 2. Clinical Manifestations 3. Diagnosis 2. Clinical

More information

HIV EPIDEMIOLOGY PROGRAM

HIV EPIDEMIOLOGY PROGRAM HIV EPIDEMIOLOGY PROGRAM ADVANCED HIV DISEASE (AIDS) QUARTERLY SURVEILLANCE SUMMARY Cases Reported as of June 30, 2002 Issued July 15, 2002 600 S. Commonwealth Ave., Suite 1920 Los Angeles, CA 90005 (Phone)

More information

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013

More information

Viral Hepatitis Diagnosis and Management

Viral Hepatitis Diagnosis and Management Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents

More information

Index. B Biological factors, 2 Brain stem encephalitis, Burkitt s lymphoma, 83, 105

Index. B Biological factors, 2 Brain stem encephalitis, Burkitt s lymphoma, 83, 105 Index A Acquired immunodeficiency syndrome (AIDS) abdomen gallbladder complications, 97, 107 109 gastrointestinal complications, 96, 105 106 liver complications, 97, 107 109 neoplasm, 99, 110 111 pancreas

More information

CMV. Inclusions predominantly in endothelial cells. Immunostaining greater sensitivity than H&E alone.

CMV. Inclusions predominantly in endothelial cells. Immunostaining greater sensitivity than H&E alone. CMV Inclusions predominantly in endothelial cells. Immunostaining greater sensitivity than H&E alone. CMV inclusions are often present in a very patchy distribution Carefully examine all levels CMV CMV

More information

The Struggle with Infectious Disease. Lecture 6

The Struggle with Infectious Disease. Lecture 6 The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV

More information

Chapter 25 Notes Lesson 1

Chapter 25 Notes Lesson 1 Chapter 25 Notes Lesson 1 The Risk of STIs 1) What is a sexually transmitted disease (STD)? Referred to as a sexually transmitted infection (STI) infectious diseases spread from person to person through

More information